comparemela.com
  1. Home
  2. Live Updates
  3. Shonali Midha - Breaking News

Latest Breaking News On - Shonali midha - Page 1 : comparemela.com

Tecvayli for MM Presents Similar Efficacy and Safety as Another Trial

Patients receiving Tecvayli for relapsed/refractory multiple myeloma had similar efficacy results and side effects, compared with another trial.

United statesShonali midhaNational cancer instituteDana farber cancer instituteInternational myeloma working groupInternational myeloma society annual meetingMyeloma society annualNational cancerAmerican societyCellular therapyDrug administration

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.

Shonali midhaHarvard medical schoolInternational staging systemDana farber cancer instituteDana farber cancerRevised international staging system

Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations

Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.

United statesShonali midhaInternational myeloma working groupDana farber cancer instituteInternational myeloma society annual meetingMyeloma society annualAmerican societyCellular therapyTeclistamab in real world patientsPatients with relapsed refractory multiple myelomaMajes tec 1 trial

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.